Abstract The activating BRAF V600 mutation is a wellestablished negative prognostic biomarker in metastatic colorectal carcinoma (CRC). A recently developed monoclonal mouse antibody (clone VE1) has been shown to detect reliably BRAF V600E mutated protein by immunohistochemistry (IHC). In this study, we aimed to compare the detection of BRAF V600E mutations by IHC, Sanger sequencing (SaS), and ultra-deep sequencing (UDS) in CRC. VE1-IHC was established in a cohort of 68 KRAS wild-type CRCs. The VE1-IHC was only positive in the three patients with a known BRAF V600E mutation as assessed by SaS and UDS. The test cohort consisted of 265 non-selected, consecutive CRC samples. Thirty-nine out of 265 cases (14.7 %) were positive by VE1-IHC. SaS of 20 randomly selected IHC negative tumors showed BRAF wildtype (20/20). Twenty-four IHC-positive cases were confirmed by SaS (24/39; 61.5 %) and 15 IHC-positive cases (15/39; 38.5 %) showed a BRAF wild-type by SaS. UDS detected a BRAF V600E mutation in 13 of these 15 discordant cases. In one tumor, the mutation frequency was below our threshold for UDS positivity, while in another case, UDS could not be performed due to low DNA amount. Statistical analysis showed sensitivities of 100 % and 63 % and specificities of 95 and 100 % for VE1-IHC and SaS, respectively, compared to combined results of SaS and UDS. Our data suggests that there is high concordance between UDS and IHC using the anti-BRAF V600E (VE1) antibody. Thus, VE1 immunohistochemistry is a highly sensitive and specific method in detecting BRAF V600E mutations in colorectal carcinoma.
Introduction
Colorectal carcinoma (CRC) is the third most malignant neoplasm in males and second most in females worldwide [1] . In a metastasized stage, the 5-year survival rate decreases to less than 10 % [2] . A combined systemic therapy including cetuximab, a monoclonal anti-EGFR antibody, increases the overall and progression-free survival in tumors bearing a wildtype of KRAS ('Kirsten rat sarcoma viral oncogene homolog') and BRAF ('v-raf murine sarcoma viral oncogene homolog B1') genes [3, 4] . In contrast, mutated BRAF is a marker of worse prognosis in CRC [5] [6] [7] . The most common genetic change in the BRAF gene of CRC is a c.1799 T > A point mutation in Exon 15, causing an amino acid exchange from valine to glutamic acid (p.V600E), which leads to a 10-fold increased kinase activity [8] [9] [10] .
Usually, analysis of the BRAF V600E status is performed using different polymerase chain reaction (PCR)-based detection methods like Sanger sequencing, pyrosequencing, and qPCR. Besides the average costs of approximately $300 per analysis [11, 12] , these techniques are time consuming and require a high-quality laboratory infrastructure with well-trained staff. Currently, Sanger sequencing is probably the most often used technique because of its reliability and high specificity.
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However, its sensitivity usually does not allow detecting mutations below a frequency of 15-20 % tumor cells [13, 14] .
Among other more sensitive techniques, next-generation sequencing technology overcomes this disadvantage and reveals low-frequency mutations in heterogeneous tumor populations. Recently, we demonstrated the reliability of this technique as a standard procedure in diagnostics of CRC using genomic DNA isolated from formalin-fixed paraffin-embedded tissues (FFPE) [15] .
In contrast, immunohistochemistry is a tissue-based, costeffective technique, which is easy to perform and routinely available in most pathology laboratories [16] . Capper et al. [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] .
In our study, we aimed to evaluate the reliability of this new antibody in detecting BRAF V600E mutations compared to conventional Sanger sequencing in a cohort of consecutive CRCs. Furthermore, we aimed to assess the sensitivity of the antibody below the detection limit of Sanger sequencing by including ultra-deep sequencing (UDS).
Materials and methods

Patients
For this study, tumor tissue, and tissue microarray (TMA) slides from two cohorts were analyzed. We have previously described a cohort of 68 KRAS wild-type CRCs [15] . Among these 68 KRAS wild-type CRCs, we identified three tumors with BRAF V600E mutations as assessed by Sanger sequencing (SaS) and UDS. All cases were diagnosed at the Institute of Surgical Pathology, University Hospital Zurich (Switzerland) between 2006 and 2011. The median age was 61 ranging from 35 to 83. Nineteen patients were females and 49 males.
The test cohort consisted of non-selected, consecutive CRC samples of 265 patients, diagnosed at the Institute of Surgical Pathology, University Hospital Zurich between 2001 and 2011. The age ranged from 21 to 95 years (median 72 years). Both sexes were equally distributed (133 females, 132 males). The study was approved by the Cantonal Ethics Committee of Zurich (KEK-ZH-NR: 2010-0093/0).
Tissue microarray construction
Original hematoxylin and eosin stained sections of all CRC samples were retrieved from the archives of the Institute of Surgical Pathology, University Hospital Zurich and reviewed by two histopathologists (antibody establishment cohort: J.R., H.M.; test cohort: M.S., A.W.). The TMAs were constructed with core replicas as described elsewhere [27] . In brief, two tissue cores (diameter 0.6 mm) of a representative tumor area of each patient were taken from a "donor" block and arranged in a new "recipient" block using a custom-built instrument. Each recipient block also included 14 colon cancer cell lines with known BRAF mutational status (six cell lines with a BRAF V600E mutation, eight cell lines with BRAF wild-type), which served as controls. Recipient blocks of the test cohort additionally include normal colorectal tissue of CRC patients as additional control tissue.
Immunohistochemistry
Immunohistochemistry (IHC) was conducted on 2-μm thick sections of both TMAs with Ventana Benchmark XT automated staining system (Ventana Medical Systems, Tucson, AZ, USA) and according to the manufacturer's instructions. Briefly, after antigen retrieval with cell conditioner 1 (Ventana Medical Systems) for 64 min and pre-primary peroxidase inhibition, the TMA slides were incubated with BRAF V600E antibodies (clone VE1, dilution 1:200; Spring Bioscience, Pleasanton, USA) for 32 min at 37°C. After that, incubation with OptiView DAB IHC Detection Kit (Ventana Medical Systems) followed. Slides were counterstained with hematoxylin and Bluing reagent for 4 min each. The reaction quality was controlled using cell lines on the TMAs with known BRAF V600E mutational status. The immunostained slides were independently evaluated by two pathologists (M.S. and M.Rö.), both blinded to the BRAF mutation status. TMA spots lacking of tumor tissue were excluded from the analysis. According to the unequivocal cytoplasmic staining of a majority of the tumor cells, TMA spots were ranked into three staining categories: score 0 for negative, score 1 for weakly/moderately positive, and score 2 for strongly positive. Of each case, the strongest immunoreactivity of the two spots was counted.
DNA extraction
Three tissue cylinders (diameter 0.6 mm) were punched from formalin-fixed, paraffin-embedded (FFPE) tissue block of each CRC patient. After extraction of genomic DNA using DNeasy Blood & Tissue Kit 250 (Qiagen, Hilden, Germany), DNA-quantification was done with NanoDrop.
Sanger sequencing
Sanger sequencing evaluating the mutational status of BRAF exon 15 was done for all IHC-positive and for 20 IHCnegative cases of the test cohort. DNA was PCR amplified (AmpliTaq Gold, Roche, Switzerland) using the primers described in Table 1 . The cycling conditions were 5 min at 95°C, 40 cycles each with 1 min at 95°C, 1 min at 53°C, 1 min at 72°C and a final elongation step of 10 min at 72°C. PCR products were purified using the Qiagen MiniElute PCR Purification Kit (Qiagen) and sequenced with a Genetic Analyzer 3130xl (Applied Biosystems) using the same primers mentioned above. A change of the electropherogram was classified as mutation, if the peak of the aberrant base (i) was clearly above background, (ii) was present in forward and reverse direction, and (iii) its height exceeded more than 10 % of the reference base peak height. Examples for Sanger sequencing declared as wild-type are shown in Supplementary Figure S1 . As a comparison of a "true" mutation, co40 is depicted as positive control in Supplementary Figure S1 .
Ultra-deep sequencing (UDS)
Additional UDS was performed to assess the BRAF status in all cases of the test cohort, which showed discordant results after IHC and Sanger sequencing. The UDS procedure is described elsewhere [15] . Shortly, an independent PCR with fusion primers including multiplex identifiers (MIDs) ( Table 1) was performed from the same DNA sample used for Sanger sequencing. Amplicon processing was done as described by the Amplicon Library Preparation and emPCR (Lib-A) Method GS Junior Titanium Series manual from Roche. 500,000 enriched beads were loaded on a 454 Junior Sequencer (Roche). Demultiplexing and variant calling was done with the Amplicon Variant Analyzer v2.7 (AVA) software from Roche. Selection criteria (at least 50 reads containing the mutation and at least 0.38 % mutation frequency) for a true positive variant are described in Rechsteiner et al. [15] .
Statistics
The calculation of the IHC VE1 sensitivity, specificity, and positive (PPV) and negative predictive value (NPV) including their 95 % confidence intervals (CI) by comparison with the combined results of both sequencing methods as "gold standard" was performed using Microsoft Excel 2010 (Microsoft Corporation, Redmond, USA). Measurement of interobserver agreement was performed using SPSS 20.0 (IBM Corporation, Armonk, USA).
Results
BRAF V600E (VE1) antibody establishment
Immunohistochemistry of cell line controls showed moderate positivity in one and strong positivity in five of the six known BRAF V600E mutated cell lines, while all eight cell lines with known BRAF wild-type were immunohistochemically completely negative. A representative staining of the cell lines is shown in Supplementary Figure S2 .
The BRAF V600E (VE1) antibody was further established in 68 KRAS wild-type CRCs with three (4.4 %) BRAF V600E mutations previously identified by SaS and UDS. All three BRAF V600E mutated CRC were immunohistochemically positive and showed strong staining reactivity with the VE1 antibody. Some CRCs showed an uncharacteristic weak to strong staining in the intracellular mucus of signet ring-like cells. In the upper row of Fig. 1 , one CRC with such a staining pattern is depicted with its Sanger sequence on the right panel without visible mutation. Another CRC with strong staining is presented in the lower row of Fig. 1 with its corresponding sequence. Due to the fact that no BRAF mutation could be detected in both CRCs by sequencing, all similar stainings in the intracellular mucus of signet ring-like cells were classified as artifacts and scored negative. All other cases were unequivocally negative, resulting in a sensitivity and specificity of 100 % each. There was a perfect interobserver agreement with a kappa value of 1.000.
VE1 expression in colorectal carcinoma of the test cohort
Both observers agreed on the interpretation of the VE1 immunohistochemical staining in all but five cases (three cases: score 0 vs. score 1; two cases: score 1 vs. score 2) resulting in a kappa value of 0.921 (p <0.01). After discussion, a consensus was obtained. One case was not evaluable because of loss of tumor material during staining process. Of the remaining 264 cases, 225 (85.2 %) were immunohistochemically negative, 19 (7.2 %) showed an IHC-score 1, and 20 (7.6 %) an IHCscore 2 (Fig. 2) .
BRAF mutational analysis by Sanger sequencing in colorectal carcinoma of the test cohort These 39 positive cases as well as 20 randomly selected IHCnegative tumors were submitted to BRAF V600E mutation analysis. SaS of the 20 randomly chosen IHC-negative cases confirmed the immunohistochemical results and showed no mutation in exon 15 of the BRAF gene. Of the 19 IHC-score 1 cases, SaS showed a BRAF V600E mutation in 13 cases and a BRAF wild-type situation in six tumors. Among the 20 IHCscore 2 cases, SaS resulted in 11 BRAF V600E mutated and in nine wild-type cases (Fig. 3) .
BRAF mutational analysis by Ultra-deep sequencing in colorectal carcinoma of the test cohort UDS was performed in 14 IHC-positive cases, which were BRAF wild-type by SaS. The DNA amount was too low for analysis in one case. Additionally, one case with IHC-score 1 in one TMA core (site 1) and IHC-score 2 on the second TMA core (site 2) was also included in the UDS analysis. Interestingly, DNA extraction from site 1 and subsequent SaS detected a BRAF mutation in the core with IHC-score 1 and none in the DNA extracted from site 2. Therefore, UDS was performed with the DNA derived from site 2 to investigate whether a low frequency mutation was missed by SaS. Moreover, a positive control was included in the UDS analysis, in which SaS detected a BRAF V600E mutation. In Fig. 4a , the total number of reads from the UDS analysis, including mutated and wild-type BRAF sequences, is shown per patient (mean 7,077 reads). In Fig. 4b , the fraction of reads with BRAF V600E mutations is depicted (mean 449 reads). In 14 cases, a BRAF V600E mutation was detected by UDS with mutation frequencies ranging from 1.85-16.36 % (Fig. 4c) . Importantly, a mutation with a frequency of 1.85 % was detected in the DNA extracted from site 2 of the abovementioned case underscoring the reliability of the VE1 staining. In the remaining case, a mutation frequency of 0.79 % with only 29 reads containing the mutation was identified which, however, was below our UDS threshold to be included as a true variant (Fig. 4c) . The positive control (co40) was successfully detected at high frequency (29 %).
Comparision of results of IHC, SaS, and UDS in colorectal carcinoma of the test cohort As a comparison of VE1-IHC, SaS, and UDS, these 15 cases and the positive control are shown in the Supplementary Figure S1 . The mutated base peak height from SaS was comparable to the percentage of the mutation found by UDS. However, all cases except for the positive control were classified as wild-type when using SaS according to our mutation detection threshold level explained in the "Materials and methods" section. In contrast, SaS and UDS results did not correlate in all cases with the VE1-IHC staining. This is mainly due to the heterogeneity of the tissue (tumor/stromal/normal cells), which is shown for one case (co25; Fig. 5 ). In this case, the TMA punches gave an IHCscore 2 which matches the TMA extraction cores of the whole tissue cut in Fig. 5 . In contrast, the punches taken for DNA extraction included one punch at a location with low tumor content which might have resulted in the wild-type classification by SaS and in the low percentage of mutated reads by UDS (10.43 %).
Together, SaS and UDS detected BRAF V600E mutations in 37 (14 %) and BRAF wild-type in 22 tumors (Fig. 3) . The case with VE1-IHC positivity and a BRAF mutation below the Statistical analysis showed a sensitivity of 100 % (95 % CI 90.75-100.00 %) and a specificity of 95.24 % (95 % CI 76.18-99.88 %) for VE1-IHC compared with combined results of both SaS and UDS as "gold standard" (see Table 2 ). The PPV was 97.44 % (95 % CI 86.52-99.94 %) and the NPV was 100.0 % (95 % CI 83.16-100.0 %) for VE1-IHC.
For SaS compared with combined results of both sequencing methods (see Table 3 ) a sensitivity of 63.16 % (95 % CI 45.99-78.19 %), a specificity of 100.0 % (95 % CI 83.16-100.00 %), a PPV of 100.0 % (95 % CI 85.75-100.00 %), and a NPV of 62.86 % (95 % CI 40.7-75.35 %) was calculated.
Discussion
Our results show a very high reliability of the VE1 immunohistochemistry detecting BRAF V600E mutations in colorectal carcinoma with a sensitivity of 100 % and a specificity of 95.24 %. Similar results were obtained in previous studies using the VE1 antibody on different tumors like malignant melanoma [24, 28] , Langerhans cell histiocytosis [26] , hairy cell leukemia [18] , papillary thyroid carcinoma [20, 23] , [19, 25] , and pulmonary adenocarcinoma [22] .
The almost perfect interobserver agreement shows that the interpretation of immunohistochemical staining results is quite clear and simple in most cases. Using the well-defined criteria ("diffuse and homogeneous granular cytoplasmic staining of tumor cells") for positivity, only few pitfalls, which have been partly described previously [20, 21, 29, 30] , occur. In colorectal tissues, sometimes, a nuclear staining of normal epithelial cells as well as an unspecific positivity of the intracellular mucus of goblet cells and signet ring-like tumor cells can be observed. Additionally, tumor-associated macrophages that sometimes show a cytoplasmic granular positivity may be difficult to differentiate from true-positive tumor cells.
According to the COSMIC database and literature, BRAF mutations are found in about 4-16 % of CRC [3, 13, 31] , which fits very well with the frequency in our test cohort bearing in mind that BRAF V600E changes counts for more than 80 % of all BRAF mutations in CRC [9] . As we performed Sanger sequencing only in 20 out of 225 VE1-IHC-negative cases, we cannot exclude that some of the remaining IHC-negative cases might have low frequency or other BRAF mutations, as well, than BRAF V600E . However, the aim of this study was rather to assess the detection limit of the VE1 antibody than the detection limit of our UDS approach. The lower rate of BRAF V600E mutations in our antibody establishment cohort (4.4 %) can be explained by a selection bias, while in contrast our test cohort consisted of non-selected, consecutive colorectal carcinoma specimen.
Our study shows some limitations of Sanger sequencing (SaS) in detecting BRAF mutations. It is well known that for successful SaS, a minimal tumor cell amount of 10-20 % is necessary. In summary, four (all VE1-IHC-score 2) out of 15 Sanger-negative cases had a tumor cell amount on TMA cores below 30 %. Three ones (all VE1-IHC-score 1), including that one on which UDS could not be performed and that one with UDS negativity due to low number of positive reads, showed a heterogeneous VE1-IHC staining pattern. In a recent study on mismatch repair protein-deficient colorectal carcinomas, Capper et al. also reported one case with a high amount of non-tumorous cells, which showed positive VE1-IHC and negative Sanger sequencing and pyrosequencing [32] . However, in eight cases with homogeneous VE1-IHC positivity (three with score 1, five with score 2) and a tumor cell percentage >60 %, SaS failed repeatedly to detect the BRAF mutation. Thus, despite the fact that we used tumor punches instead of whole sections for DNA extraction, which usually results in a higher tumor cell load, SaS failed in 38 % of our cases to detect the BRAF V600E mutation. One critical aspect of punching the tumor area for DNA extraction is to allocate and to hit the right area for punching. Such a case is shown in Fig. 5 , where one punch at a location with low tumor content was included. This punch might have resulted in the wild-type classification by SaS and in the low percentage of mutated reads by UDS. Another case reflecting the same problem was investigated by comparing sequencing data obtained from DNA extracted from two different sites of a tumor which both were positive for VE1-IHC. SaS detected a BRAF V600E mutation only in one of these two sites. Subsequent UDS of the Sanger-negative material revealed the same mutation at low frequency. It may be speculated if VE1-IHC, which can also highlight single tumor cells, was more sensitive detecting the BRAF mutation than SaS or if VE1-IHC was false positive in these tumor cells. The fact that UDS detected the mutation at low frequency rather suggests a higher sensitivity of VE1-IHC. Whether, in this case, the low mutation frequency was due to the contamination of normal cells or due to intratumoral heterogeneity remains elusive. Assuming the latter variant, these results might reflect true intratumoral heterogeneity of BRAF mutation, which has been reported as rare events (1-3 %) in primary CRC [33, 34] .
Another reason why, in our study, 38 % of the BRAF mutations were missed by SaS might be the stringent selection criteria we applied for classifying a mutation as true by SaS. Retrospectively, one might adjust the detection threshold as in most cases of the 15 previously classified wild-type cases a mutated base peak was visible in SaS.
Our results agree with previous studies comparing SaS with other sensitive detection methods like pyrosequencing or deep sequencing. Guerra et al. reported a similar result comparing BRAF mutational status of macrodissected papillary thyroid carcinoma by SaS and pyrosequencing [35] . Thus, VE1-IHC seems to be sensitive enough to overcome the problem of tissue and tumor heterogeneity. Taken together, we demonstrate the high sensitivity and specificity of detecting BRAF V600E mutations in colorectal carcinoma by a new mutation-specific antibody. Our IHC results agree with two other recently published studies investigating the VE1 antibody on CRC specimens [29, 36] . Both groups reported a high concordance between VE1-IHC and pyrosequencing [29] or multiplex allelic-specific PCR-based assay [36] as reference methods. In contrast, a study by Adackapara et al. [30] showed a much lower sensitivity (35 %) for VE1-IHC on CRC specimen compared to pyrosequencing results. They used a manual technique with overnight incubation for VE1-IHC. Therefore, methodological differences could explain the difference to ours and other studies.
Our study represents the first comparison between UDS and VE1-IHC in CRC and we demonstrate a very high concordance between UDS and VE1-IHC. In the light of the relatively high costs and demanding infrastructure of ultradeep sequencing as well as the lower sensitivity of SaS, the VE1-IHC, which can be performed routinely in probably most pathological institutes, seems to be a reliable, simple, and cheap primary tool to analyze BRAF V600E status for diagnostic, predictive, and prognostic purposes. Only VE1-negative or equivocal cases may be further investigated by more sensitive methods like ultra-deep sequencing.
